Commenting on the patient safety alert, Douglas Twenefour, head of care at Diabetes UK, said: The ongoing shortages of GLP-1 medications are having serious implications for many people with T2DM and are still a major concern
Recent literature has associated the use of GLP-1 receptor agonists with an increased likelihood of developing diabetic lumbosacral radiculoplexus neuropathy (DLRPN) and common fibular neuropathy (CFN), with a recently published case-control study on this topic indicating a 51% and 30% increased risk, respectively [9]
SkinnyRx does not include behavior coaching, nutrition support, or fitness guidance
Lambeth, J
When your levels dip, you might notice fatigue, brain fog, frequent colds, or dullness in your skin
Journal of Pharmaceutical and Biomedical Analysis, 176 , 112796